APA (7th ed.) Citation

Patel, C. G., Rangachari, L., Patti, M., Griffin, C., Shou, Y., & Venkatakrishnan, K. (2019). Characterizing the Sources of Pharmacokinetic Variability for TAK‐117 (Serabelisib), an Investigational Phosphoinositide 3‐Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy. Clinical pharmacology in drug development, 8(5), 637-646. https://doi.org/10.1002/cpdd.613

Chicago Style (17th ed.) Citation

Patel, Chirag G., Lakshmi Rangachari, Mark Patti, Celina Griffin, Yaping Shou, and Karthik Venkatakrishnan. "Characterizing the Sources of Pharmacokinetic Variability for TAK‐117 (Serabelisib), an Investigational Phosphoinositide 3‐Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy." Clinical Pharmacology in Drug Development 8, no. 5 (2019): 637-646. https://doi.org/10.1002/cpdd.613.

MLA (9th ed.) Citation

Patel, Chirag G., et al. "Characterizing the Sources of Pharmacokinetic Variability for TAK‐117 (Serabelisib), an Investigational Phosphoinositide 3‐Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy." Clinical Pharmacology in Drug Development, vol. 8, no. 5, 2019, pp. 637-646, https://doi.org/10.1002/cpdd.613.